TITLE

1

4

5

- 2 Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a
- 3 symptomatic control group.

AUTHORS

- 6 Ana Beatriz Cazé Cerón ana.caze@ufba.br Universidade Federal da Bahia,
- 7 Salvador, Bahia, Brazil
- 9 Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil;
- 10 Universidade Federal da Bahia, Salvador, Bahia, Brazil
- 11 Adriele Pinheiro Bomfim, M. Sc., <u>adrielepbomfim@gmail.com</u> Instituto Gonçalo
- Muniz, Fiocruz, Salvador, Brazil; Universidade Federal da Bahia, Salvador, Bahia,
- 13 Brazil
- 15 Saúde Pública da Bahia; Instituto Goncalo Moniz, Fiocruz, Salvador, Bahia, Brazil
- 16 > Amanda Canário Andrade Azevedo, MD, M.Sc. amandacanario@gmail.com -
- Hospital Santa Izabel, Santa Casa da Bahia, Salvador, Bahia, Brazil
- 18 Michelle Queiroz Aguiar Brasil, MD, M. Sc. michelleqas@gmail.com Instituto
- 19 Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil; Federal University of Bahia,
- 20 Salvador, Bahia, Brazil
- 21 Nara Rúbia Santos <u>narabusiness@hotmail.com</u> Departamento de Vigilância em
- 22 Saúde/Vigilância Epidemiológica, Campo Formoso, Bahia Brazil
- 23 Antônio Ricardo Khouri Cunha, PhD <u>ricardo_khouri@hotmail.com</u> Department of
- 24 Microbiology, Immunology and Transplantation, Rega Institute for Medical Research,
- 25 Laboratory of Clinical and Epidemiological Virology, Belgium; Instituto Gonçalo
- 26 Moniz, Fiocruz, Salvador, Bahia, Brazil

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

➤ Jennifer Dan, MD, PhD – jdan@ucsd.edu - Center for Infectious Disease and Vaccine Research, la Jolla Institute for Immunology (LJI); Department of Medicine, Division of Infectious Disease and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA > Antonio Carlos Bandeira, MD, PhD, - antoniobandeira@gmail.com - UNI-FTC-Faculdade Tecnologia Ciências Medical School, Bahia; Central State Laboratory LACEN-Bahia; Infectious Diseases Advisor Luciano Pamplona de Goes Cavalcanti, MD, PhD - pamplona.luciano@gmail.com -Universidade Federal do Ceará, Fortaleza, Ceará, Brazil; Centro Universitario Christus, Fortaleza, Ceará, Brazil Manoel Barral-Netto, MD, PhD - manoel.barral@fiocruz.br - LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Universidade Federal da Bahia, Salvador, Bahia, Brazil > Aldina Maria Prado Barral - aldina.barral@fiocruz.br - Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil; Instituto de Investigação em Imunologia, São Paulo, São Paulo, Brazil > Cynara Gomes Barbosa*, PhD - <u>cynara.barbosa@gmail.com</u> - Universidade Federal da Bahia, Salvador, Brazil Viviane Sampaio Boaventura de Oliveira*, MD, PhD, - vsboaventura@gmail.com -LIB and LEITV Laboratories, Instituto Goncalo Moniz, Fiocruz, Salvador, Bahia, Brazil; Universidade Federal da Bahia, Salvador, Bahia, Brazil *Those authors equally supervised this study **Corresponding author** Viviane Sampaio Boaventura Email address: vsboaventura@gmail.com

Telephone: + 55 71 31762211
Postal address: 121 Waldemar Falcão Street, Candeal, Salvador, Bahia, Brazil, CEP 40296
54
55
56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

ABSTRACT Background There is limited data on the prevalence and risk factors for long COVID, with a shortage of prospective studies with appropriate control groups and adequate sample size. We therefore performed a prospective study to determine the prevalence and risk factors for long COVID. Methods We recruited patients age ≥ 15 years who were clinically suspected of having acute SARS-CoV-2 infection from September 2020 to April 2021. Nasopharyngeal swabs were collected for RT-PCR 3-5 days post symptom onset. Clinical and sociodemographic characteristics were collected using structured questionnaires from persons positive and negative for SARS-COV-2. Follow-up was performed by telephone interview to assess early outcomes and persistent symptoms. For COVID-19 cases, 5D-3L EuroQol questionnaire was used to assess the impact of symptoms on quality of life. Results We followed 814 participants (412 COVD-19 positive and 402 COVID-19 negative persons) of whom the majority (741 / 814) had mild symptoms. Both the COVID-19 positive and the COVID-19 negative groups had similar sociodemographic and clinical characteristics, except for the rate of hospitalization (15.8% vs 1.5%, respectively). One month after disease onset, 122 (29.6%) individuals reported residual symptoms in the COVID-19 positive group or the long COVID group versus 24 (6%) individuals in the COVID-19 negative group. In the long COVID group, fatigue, olfactory disorder, and myalgia were the most frequent symptoms which occurred in the acute phase. Compared to recovered patients, female sex, older age and having > 5 symptoms during the acute phase were risk factors for long COVID. Quality of life was evaluated in 102 out of 122 cases of long COVID with 57 (55.9%) reporting an impact in at least one dimension of the EuroQol 5D-3L questionnaire.

In this prospective study consisting predominantly of patients with mild disease, the persistence of symptoms after acute disease was highly associated with long COVID-19 (29.6% vs 6% of COVID negative group). The risk factors for long COVID were older age, female sex, and polysymptomatic acute disease.

KEYWORDS

COVID-19; SARS-CoV-2; long COVID; frequency; risk factor; outpatients; post-COVID syndrome; persistent symptoms; post-Acute COVID Syndrome; PASC.

BACKGROUND

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Long COVID has received less attention from the scientific community than acute COVID-19, representing less than 2% of COVID-19 publications in PubMed Clinical Queries, August 31, 2022). Several important aspects remain undefined such as its prevalence. Long COVID has been reported to effect between 7.5% to 89% of patients [1, 2, 29, 30]. Most of these studies do not include well-matched controls which is important because long COVID-symptoms are nonspecific and may be attributed to other factors such as the physical and mental impact of having COVID-19 infection or hospitalization [3,4]. Prospective studies enrolling symptomatic individuals with and without confirmed COVID-19 are necessary to better estimate the prevalence of long COVID and its associated risk factors. Long COVID is anticipated to have a large impact on the healthcare system [5]. Identifying risk factors for developing long COVID will help mitigate its impact. Some risk factors have been suggested for long COVID; however, these studies consisted of previously hospitalized patients [1] or were retrospective analyses from electronic health records of not hospitalized patients (31). We therefore performed a longitudinal study of patients with COVID-like symptoms who tested positive or negative for SARS-CoV-2 to assess the

METHODS

Study population

We recruited individuals age \geq 15 years with clinical suspicion of acute SARS-CoV-2 infection in health care units from three municipalities of Bahia State-Brazil (Irecê, Campo Formoso, and Lauro de Freitas). Individuals who had difficulty in reporting symptoms, those who were > 20 days post symptom onset at the time of recruitment, or those who reported

prevalence and risk factors for long COVID and its impact on the quality of life.

SARS-CoV-2 re-infection were excluded. The study was conducted from September 2020 to

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

April 2021. The ancestral strain or gamma variant of SARS-CoV-2 was dominant in Brazil from November 2020 to August 2021 (Additional file 1: Fig S1-2) [6]. Exposure measurement All patients were tested for COVID-19 by nasopharyngeal RT-PCR. Only individuals who had an RT-PCR in the first ten days of disease onset were considered eligible for the follow-up. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) protocol was followed. Recruitment strategy and data collected Consecutive in-person recruitment included the application of a structured survey (Questionnaire 1) using Research Electronic Data Capture (REDCap) software hosted by the Gonçalo Moniz Institute (IGM/FIOCRUZ) in Bahia, Brazil. The following information was collected: sociodemographic characteristics (age, gender, skin color, body mass index, anthropometric data, municipality of residence), comorbidities (hypertension, diabetes, heart disease, chronic lung disease, other), date of symptom onset, acute symptoms (fever, myalgias, arthralgias, cough, shortness of breath, nasal congestion, sneezing, coryza, sore throat, sinus pain, retroocular pain, ear pain, headache, chest pain, chest discomfort, rash, abdominal pain, loss of appetite, vomiting, diarrhea (2 or more episodes in the last 24 hours), weakness, fatigue, lightheadedness or fainting, loss of smell, and loss of taste). Follow-up and outcome measurement SARS-CoV-2 positive (COVID-19) and negative (non-COVID-19) patients who reported COVID-like symptoms were followed. Negative cases were recruited on the same

day as positive cases before nasopharyngeal RT-PCR. The date of symptom onset was considered Day zero. A second structured questionnaire (Questionnaire 2) was conducted 30 to 60 days after disease onset by telephone to document the RT-PCR result, acute symptoms, and clinical outcome. Participants were classified as non-hospitalized or hospitalized in the intensive care unit (ICU) or non-ICU). To avoid memory bias, questionnaires 1 and 2 were applied in a short interval of time.

A third structured questionnaire was conducted 60 to 250 days after disease onset by telephone to evaluate residual symptoms (Questionnaire 3). Questions included residual or new symptoms: cough, fatigue, shortness of breath, headache, chest pain, dysphonia, dysphagia, loss of appetite, loss of smell, loss of taste, myalgias, arthralgias, fever, and other non-listed symptoms. Patients reporting suspected or confirmed re-infection were excluded from the final analysis. A schematic diagram of the study is provided (**Additional file 1**: **Fig S3**).

Outcomes of interest

Long COVID was defined according to the Centers for Disease Control and Prevention classification [7]. Persistence of symptoms was defined as the presence of at least one residual symptom > 1 month post disease onset. The list of residual symptoms presented on the questionnaire was based on literature [8,9].

The European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) was conducted via telephone to assess health dimensions: mobility, self-care, daily activities, pain/discomfort and anxiety/depression. The EQ-visual analogue scale (VAS) was also conducted with 0 rated as worst health imaginable and 100 as the best imaginable health [10].

Statistical analysis

Categorical data were described using absolute values and percentages/frequencies. Continuous data were described using mean (standard deviation, SD) and median (interquartile range, IQR). The correlation matrix was constructed based on the frequency of persistent symptoms reported by the patients. Multivariable logistic regression was performed to explore risk factors related to long COVID, applying the odds ratios (OR; 95% CI). Analyses were done in R (version 4.2.0) [26].

RESULTS

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

In total, 1,268 patients with suspected SARS-CoV-2 infection were recruited and answered the first questionnaire 4 days (range of 3-5 days) post symptom onset. After excluding cases outside the RT-PCR recommended window period, reported re-infection, or those lost to follow-up, 814 (64.2%) patients were considered eligible for the analysis of residual symptoms (Fig. 1, Additional file 1: Fig. S3). Questionnaires 2 and 3 were conducted 40 (31-59) days and 102 (63-150) days post symptom onset, respectively. No difference in sociodemographic data and frequency of positive RT-PCR were observed between the included (n=814) and excluded (n=454) participants (Additional file 1: Table S1). Among the included participants, 412 tested positive (COVID-19 group) and 402 tested negative (non-COVID-19 group) for SARS-CoV-2. Demographic characteristics for the COVID and non-COVID groups were as follows, respectively: a median age of 36 (IQR) and 34 (IQR) years, female gender of 55% and 64%, mild disease in 84% and 99% (**Table 1**). More patients were hospitalized in the COVID-19 group compared to the non-COVID-19 group (15.9% vs 1.5%, respectively, **Table 1**). Follow-up time was 3.3 months for the COVID group and 3.7 months for the non-COVID group (Additional file 1: Fig. S4). After one month post disease onset, per the CDC definition for long COVID

(September 16, 2021), 122/412 (29.6%) individuals from the COVID group reported residual

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

symptoms and were classified as long COVID cases, while the remaining 290 individuals were fully recovered. From the non-COVID group, residual symptoms were reported by only 24 (6%) individuals (**Table 1**). Among long COVID cases, 57 (13.2%) presented with more than two residual symptoms. Within the COVID group, fatigue (56, 13.7%), olfactory disorder (42, 9.9%), myalgia (36, 8.7%), gustatory disorder (27, 6.6%), and headache (26, 6.1%) were the residual symptoms most frequently reported (Fig. 2). These symptoms started mainly during the acute phase. Other symptoms not reported during the acute phase, such as memory loss and hair loss, were reported by the patients with long COVID (Additional file 1: Table S2). Compared to those who recovered, the long COVID group had more women (63.1% vs. 52.1%) and older individuals [40 (32-51) vs. 35 (28-47) years] (**Table 2**). Hospitalization for acute disease was comparable between long COVID (21/122, 17.2%) and recovered patients (44/290, 15.2%). The risk of long COVID increased with age and was significant for persons 50 years of age or older (OR 2.44, 95% CI 1.29-4.66). Individuals with > five symptoms in the acute phase (OR 3.15, 95% CI 1.37-8.55) and females (OR 1.55, 95% CI 0.99-2.44) were more likely to develop long COVID (**Table 3**). Co-occurrence of long COVID symptoms was also observed. Fatigue was reported by at least 50% of those that complained of gustatory dysfunction, anorexia, dysphonia, chest pain, headache, breathlessness, or myalgia. Moreover, olfactory dysfunction was reported by 80% of participants with gustatory dysfunction (**Additional file 1: Fig. S5**). Finally, we have evaluated the impact of long COVID on the quality of life. The EQ-5D-3L questionnaire was administered to 102 out of 122 patients. Fifty-seven patients (55.8%) reported alteration in at least one dimension of QoL, and 41 patients (41.1%) had an impact in the dimension of pain and depression (Additional file 1: Table S3).

DISCUSSION

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

We have followed RT-PCR positive and negative patients with COVID-like symptoms from the first days post symptom onset to 63-150 days post symptom onset to determine the prevalence of long COVID-19. Long COVID occurred in almost one-third of test-positive cases, the majority with mild acute disease, compared to 6% of negative patients with residual symptoms, supporting the association between SARS-CoV-2 infection and residual symptoms. The risk of long COVID increased with age > 50 years old, female gender, and the development of > five symptoms during the acute phase. Together these findings demonstrate that residual symptoms after mild disease were mainly associated with COVID-19 with well-defined demographic and clinical risk factors. The proportion of patients with COVID-19 who developed long COVID has varied from 7.5% to 89% [1, 2, 29, 30]. Most studies only included patients who tested positive for SARS-CoV-2. One strength of our study is the inclusion of a comparator group of symptomatic patients, recruited in the same time/location, who tested negative by SARS-CoV-2 RT-PCR. Additionally, most symptoms investigated in the follow-up questionnaires were evaluated at the time of recruitment, in a blinded manner, prior to the SARS-CoV-2 test result. The inclusion of a control group is important considering that many residual symptoms attributed to long COVID, such as fatigue and headache, are nonspecific and could be triggered or aggravated by stress and psychosocial problems connected to the global health crisis [11-13]. Indeed, we observed that non-confirmed COVID-19 cases reported similar residual symptoms after acute illness, albeit at a much lower frequency. Few studies have included a control group composed of symptomatic patients that tested negative for SARS-CoV-2 [14, 31]. In a cohort of healthcare workers, olfactory disorders and hair loss were

related to long COVID while positive and negative cases both had similar frequencies of

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

exhaustion/burnout and fatigue [14]. In a population-based digital retrospective cohort including outpatients and well-matched controls, 62 symptoms were associated with long COVID [31]. The inclusion of a control group is even more valuable for hospitalized cases, considering the increased risk of sequelae associated with iatrogenic procedures for treating severe disease [15]. Together, these findings highlight the importance of including a control group when determining the frequency of sequelae to avoid overestimating long COVID cases. We observed a similar proportion of long COVID in groups with mild and moderate/severe disease [16,17]. We enrolled a small number of severe COVID-19 cases and therefore could not conclude an association between disease severity and sequelae. Severe COVID-19 increases the risk of long COVID by 1.2 to 8x among hospitalized cases compared to those not hospitalized [18]. Nonetheless, the finding that long COVID occurs in a significant proportion of individuals after mild disease highlights its potential impact on the healthcare system, as COVID-19 variants and sub-variants continue to spread worldwide. Fatigue was the most frequent sequelae and occurred isolated or associated with other clinical manifestations. As previously reported [19], we also observed a vast impact of long COVID on the quality of life. Although the mechanism is unknown, an exacerbation of the immunological response and multisystemic involvement [20] seems to be involved. Studies investigating the pathogenesis of long COVID are essential to improve treatment and attenuate the impact. Similar to previous studies [3, 9, 17, 21-23, 31], we found that long COVID was more prevalent in women and could be attributed to a greater propensity for women to go to a clinic [22]. Indeed, females represented 55% of the COVID group and 64% of the non-COVID group in our study. Sex hormone differences in immune response [24] and autoimmunity triggered by SARS-CoV-2 have been suggested to be involved in the disease

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

pathogenesis of long COVID [23]. Other studies have found that individuals with more symptoms during the acute phase were at a higher risk for developing long COVID [9, 14]. There are conflicting results regarding age in the risk for developing long COVID. In a cohort of healthcare workers in Switzerland, the majority of whom had mild disease, young age was associated with a higher risk for developing long COVID (14), in contrast to our findings. Additional prospective studies including multicenter cohorts with larger sample sizes and older patients should be performed to evaluate if the risk for developing long COVID differs among age groups, racial groups, and ethnicities. Prospective studies to develop predictive models and algorithms should be performed for the early detection of long COVID cases. Long COVID has different definitions. We have used the CDC's definition for long COVID (September 16, 2021), that includes persistence of symptoms after four weeks of the onset of disease. Recently, a WHO-coordinated Delphi consensus established a period of more than three months after COVID-19 onset for the case definition of long COVID [25]. In our study, only 445 of the calls were performed three months after disease onset. By this definition, long COVID was detected in 68/216 (31.5%) of our patients. Residual symptoms were also observed in 17/229 (7.4%) of the non-COVID-19 patients. As observed in our study, the prevalence of long COVID may vary between studies in the absence of a universal consensus to define long COVID [4]. This impacts the estimation of the prevalence of long COVID cases worldwide. This study has some limitations. The loss to follow-up was around 36% of patients and may have influenced the estimates of residual symptoms. Similar demographic and clinical characteristics were observed among patients that were included and the ones that were lost to follow-up. In addition, most participants were young, with mild disease, which does not permit generalizing these findings to the elderly and those with severe disease.

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

Moreover, the participants were aware of their diagnosis of COVID-19 when questionnaire 3 was applied, which may have led to an overestimation of persistent symptoms. Finally, the short time to follow-up did not allow for an analysis of the duration of long COVID. CONCLUSIONS Long COVID was detected in 29.6% of patients with mild COVID-19 disease, with older age, female sex, and polysymptomatic acute disease as the main risk factors for persistent symptoms. Estimating the long COVID prevalence is important for preparing the healthcare system to assist and guide these patients. Further studies should be conducted to evaluate the impact of different variants of SARS-CoV-2 on long COVID and the potential impact of vaccines in reducing residual symptoms. LIST OF ABBREVIATIONS STROBE – Strengthening the Reporting of Observational Studies in Epidemiology RT-PCR – Reverse Transcriptase Polymerase Chain Reaction REDCap – Research Electronic Data Capture software IGM/FIOCRUZ – Gonçalo Moniz Institute ICU – Intensive Care Unit SD – Standard Deviation IQR – Interquartile Range

TABLES

314

315

316

Table 1: Clinical, sociodemographic characteristics and frequency of residual symptoms for

COVID-19 and non-COVID-19 cases.

Characteristic ¹	COVID-19 cases	Non-COVID-19 cases	
Characteristic	n = 412	n = 402	
Age	36 (28-48)	34(25-43)	
Age group			
15-29	126 (30.6%)	167 (41.5%)	
30-39	123 (29.9%)	106 (26.4%)	
40-49	75 (18.2%)	82 (20.4%)	
>50	88 (21.4%)	47 (11.7%)	
Female sex	228 (55.3%)	259 (64.4%)	
Body mass index (BMI)	27 (23.5-29.8)	26.1 (23.5-29.1)	
Number of acute symptoms	11 (8-14)	10 (7-13)	
Comorbidities	148 (35.9%)	131 (32.5%)	
Diabetes mellitus	12 (11.0%)	11 (2.7%)	
Respiratory allergy	95 (23.3%)	126 (31.3%)	
Obesity	102 (24.8%)	86 (21.4%)	
Normal	310 (75.2%)	316 (78.6%)	

Obese (BMI 30-34)	21 (5.1%)	17 (4.2%) 67 (16.7%)	
Overweight (BMI 35-39)	79 (19.2%)		
Extremely obese (BMI >40)	2 (0.5%)	2 (0.5%)	
Number of comorbidities			
1	101 (24.5%)	90 (22.4%)	
>1	47 (11.4%)	41 (10.2%)	
Type of Hospitalization			
Outpatient (mild)	346 (84.2%)	395 (98.5%)	
Hospitalization non-ICU (moderate)	59 (14.4%)	6 (1.5%)	
Hospitalization ICU (severe)	6 (1.5%)	0 (0%)	
At least one residual symptom > 1 month after disease onset	122 (29.6%)	24 (5.8%)	
Number of residual symptoms (median)	1 (1-2)	2 (1-3)	
1	65 (15.8%)	9 (2.2%)	
>1	57 (13.2%)	13 (5.4%)	
Call Time Persistent Symptoms	3.35 (2.1-5.2)	3.65 (2.1-4.9)	

^{318 &}lt;sup>1</sup>n(%) or Median (IQR)

319

Table 2: Clinical, sociodemographic characteristics and frequency of residual symptoms for

321 COVID cases with or without sequelae.

	No Sequelae	Sequelae	
Characteristic ¹	n=290	n=122	
Age	35 (28, 47)	40 (32, 51)	
Age group			
15-29	99 (34.1%)	27 (22.1%)	
30-39	85 (29.3%)	38 (31.1%)	
40-49	51 (17.9%)	24 (19.7%)	
>50	55 (19.0%)	33 (27.0%)	
Female sex	151 (52.1%)	77 (63.1%)	
BMI	26.9 (23.5, 29.7)	27.2 (23.8, 30.1)	
Number of acute symptoms	11 (7, 14)	12 (9, 15)	
Comorbidities	101 (34.8%)	47 (38.5%)	
Diabetes mellitus	6 (2.1%)	6 (2.1%)	
Respiratory allergy	63 (21.9%)	32 (26.2%)	
Obesity	70 (24.1%)	32 (26.2%)	
Obese (BMI 30-34)	12 (4.1%)	9 (7.4%)	
Overweight (BMI 35-39)	57 (19.7%) 22 (18.0%)		

Extremely obese (BMI >40)	1 (0.3%)	1 (0.3%)	
Number of comorbidities			
1	75 (25.9%)	26 (21.3%)	
>1	26 (9.0%)	21 (17.2%)	
Time of disease onset	3.30 (2.00, 5.10)	3.75 (2.12, 5.55)	
Hospitalization	44 (15.2%)	21 (17.2%)	

^{1.} n(%) or Median (IQR)

322

323

Table 3. Multivariable analysis of odds ratio (lower and upper confidence intervals) for presenting long COVID symptoms.

	OR	LCI*	UCI*	P value
Age group (reference 14-29				
years				
30-39	1.71	0.95	3.12	0.078
40-49	2.04	1.02	4.10	0.045
≥ 50	2.44	1.29	4.66	0.006
Female sex	1.55	0.99	2.44	0.055
> 5 acute symptoms	3.15	1.37	8.55	0.012

^{*}LCI and UCI - lower and upper confidence intervals, respectively

328 FIGURES

Fig 1. Flowchart of the study population.

329





Fig. 2: Frequency of acute and residual symptoms for COVID-19 and non-COVID-19 cases.



DECLARATIONS

336

- Ethics approval and consent to participate: Informed consent was obtained from all
- 338 participants. The Ethics in Research Committee of the Gonçalo Moniz Research Center
- approved this study (approval no. 4.315.319/202).
- 340 **Consent for publication**: Not applicable
- 341 Availability of data and materials: The dataset generated and/or analyzed during the
- 342 current study are not publicly available due to legal and ethical restrictions. Dataset are
- 343 available upon request.
- Funding: This study was supported by MCTI/CNPq/FNDCT/MS/SCTIE/Decit (n° 07/2020)
- 345 MB-N, AB and VSB are research fellows from CNPq, the Brazilian National Research
- Council. T.C-S. is a PhD student at the Post-Graduation Program in Health Sciences-UFBA,
- 347 which is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-
- 348 Brasil, finance code 001.
- 349 Competing interests: The authors do not have conflicts of interests to declare for this work.
- 350 Authors' contributions: A.B.C.C. and V.B structured the original draft. V.B. and C.B. were
- 351 responsible for conceptualization and methodology. A.P.B., G.L.S, A.C.A.A, M.Q.A.B,
- N.R.S and A.B.C.C collected data from the patients. T.C.S made the formal analysis

- 353 statistics. A.M.P.B. and V.B. participated in the project administration and in the funding
- acquisition. TCS, JD, ACB, LPGC, MBN, ABN, CGB substantively revised the manuscript.
- 355 All authors read and approved the final manuscript.
- 356 **Acknowledgements**: We wish to thank all patients who were willing to participate in the
- 357 study. In addition, we would like to thank Hospital Aeroporto and Municipal Health
- 358 Secretariats of Irecê and Campo Formoso for logistical support and to Roberta de Carvalho
- 359 Freitas for patient-related support.

362 **REFERENCES**

- 363 [1] Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global
- 364 Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A
- 365 Meta-Analysis and Systematic Review. J Infect Dis 2022.
- 366 https://doi.org/10.1093/infdis/jiac136.
- 367 [2] Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of
- 368 Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw
- 369 Open 2021;4:e2111417-e2111417.
- 370 <u>https://doi.org/10.1001/JAMANETWORKOPEN.2021.11417</u>.
- 371 [3] Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for
- 372 characterizing long COVID. Nat Med 2021; 27:1129–30. https://doi.org/10.1038/s41591-
- 373 <u>021-01402-w</u>.
- 374 [4] Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al.
- 375 Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a
- 376 systematic review and meta-analysis. Clin Microbiol Infect 2022.
- 377 https://doi.org/10.1016/j.cmi.2022.01.014.

- 378 [5] Kelly BD, Gulati G, Kelly B. Long COVID: the elephant in the room n.d.
- 379 <u>https://doi.org/10.1093/qjmed/hcab299</u>. Accessed Apr 15, 2022.
- 380 [6] Nagib W. Home [Internet]. Genomahcov Fiocruz. Available from:
- 381 http://www.genomahcov.fiocruz.br/. Accessed Apr 5, 2022.
- [7] CDC. COVID-19 and Your Health [Internet]. Centers for Disease Control and Prevention.
- 383 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/.
- 384 Accessed May 5, 2022.
- 385 [8] Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A,
- et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis.
- 387 Sci Reports | 123AD;11:16144. https://doi.org/10.1038/s41598-021-95565-8.
- 388 [9] Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al.
- 389 Attributes and predictors of long COVID. Nat Med 2021 274 2021;27:626-31.
- 390 https://doi.org/10.1038/s41591-021-01292-y.
- 391 [10] EQ-5D User Guides EQ-5D [Internet]. EuroQol. 2022. Available from:
- 392 https://euroqol.org/publications/user-guides/. Accessed Apr 10, 2022.
- 393 [11] Bartoszek A, Walkowiak D, Bartoszek A, Kardas G. Mental well-being (Depression,
- 394 loneliness, insomnia, daily life fatigue) during COVID-19 related home-confinement—A
- 395 study from Poland. Int J Environ Res Public Health 2020;17:1–12.
- 396 https://doi.org/10.3390/ijerph17207417.
- 397 [12] Usher K, Bhullar N, Jackson D. Life in the pandemic: Social isolation and mental health.
- 398 J Clin Nurs 2020;29:2756–7. https://doi.org/10.1111/JOCN.15290.
- 399 [13] Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. Rapid
- 400 Review The psychological impact of quarantine and how to reduce it: rapid review of the
- 401 evidence. WwwThelancetCom 2020;395. https://doi.org/10.1016/S0140-6736(20)30460-8.

- 402 [14] Strahm C, Seneghini M, Güsewell S, Egger T, Leal O, Brucher A, et al. Symptoms
- 403 compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection
- 404 results of a prospective multicenter cohort. Clinical Infectious Diseases. 2022 Jan 28.
- 405 <u>https://doi.org/10.1093/cid/ciac054</u>
- 406 [15] Evans RA, Leavy OC, Richardson M, Elneima O, McCauley HJC, Shikotra A, et al.
- 407 Clinical characteristics with inflammation profiling of long COVID and association with 1-
- 408 year recovery following hospitalisation in the UK: a prospective observational study. Lancet
- 409 Respir Med 2022;0. https://doi.org/10.1016/S2213-2600(22)00127-8/
- 410 [16] Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent
- 411 fatigue following SARS-CoV-2 infection is common and independent of severity of initial
- 412 infection. PLoS One 2020;15: e0240784. https://doi.org/10.1371/JOURNAL.PONE.0240784.
- 413 [17] Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mul G, et al. Female gender
- 414 is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect
- 415 2021; 1. https://doi.org/10.1016/j.cmi.2021.11.002.
- 416 [18] Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-
- 417 COVID-19 symptoms 6 months after acute infection among hospitalized and non-
- 418 hospitalized patients. Clin Microbiol Infect 2021;27:1507–13.
- 419 https://doi.org/10.1016/j.cmi.2021.05.033.
- 420 [19] Kim Y, Kim S-W, Chang H-H, Kwon KT, Hwang S, Bae S. One Year Follow-Up of
- 421 COVID-19 Related Symptoms and Patient Quality of Life: A Prospective Cohort Study.
- 422 Yonsei Med J 2022;63:499–510. https://doi.org/10.3349/YMJ.2022.63.6.499.
- 423 [20] Abboud H, Abboud FZ, Kharbouch H, Arkha Y, El Abbadi N, El Ouahabi A. COVID-
- 424 19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System.
- 425 World Neurosurg 2020;140:49–53. https://doi.org/10.1016/J.WNEU.2020.05.193.

- 426 [21] Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, á Steig B, Gaini S, et al.
- 427 Long COVID in the Faroe Islands: A Longitudinal Study Among Nonhospitalized Patients.
- 428 Clin Infect Dis 2021;73:e4058–63. https://doi.org/10.1093/cid/ciaa1792.
- 429 [22] Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-
- 430 COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective
- 431 cohort study. Lancet Reg Heal Eur 2021;6:100122.
- 432 <u>https://doi.org/10.1016/j.lanepe.2021.100122</u>.
- 433 [23] Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent
- 434 Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A
- 435 Prospective Cohort Study. Clin Infect Dis 2022;74:1191-8.
- 436 https://doi.org/10.1093/cid/ciab611.
- 437 [24] Stewart S, Newson L, Briggs TA, Grammatopoulos D, Young L, Gill P. Long COVID
- risk a signal to address sex hormones and women's health. Lancet Reg Heal Eur 2021;11.
- 439 https://doi.org/10.1016/J.LANEPE.2021.100242.
- 440 [25] Soriano JB, Murthy S, Marshall JC, Relan P, Diaz J V. A clinical case definition of
- 441 post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2021.
- 442 https://doi.org/10.1016/s1473-3099(21)00703-9.
- 443 [26] R Core Team (2021). R: A language and environment for statistical computing. R
- 444 Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
- 445 [27] Rede Genômica Fiocruz. https://www.genomahcov.fiocruz.br/. Accessed May 5, 2022.
- 446 [28] BioRender. https://biorender.com/. Accessed May 6, 2022.
- 447 [29] Ofice for National Statistics. The prevalence of long COVID symptoms and COVID-19
- 448 complications. 2020. Available from: https://www.ons.gov.uk/news/statementsandletters/
- theprevalenceofongcovidsymptomsandcovid19complications. Accessed May 20, 2022.

450 [30] CDC. Nearly One in Five American Adults Who Have Had COVID-19 Still Have "Long 451 COVID" [Internet]. Centers for Disease Control and Prevention. 2022. Available from: 452 https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm#:~:text=Over 453 all%2C%201%20in%2013%20adults,long%20COVID%20than%20younger%20adults. 454 Accessed May 21, 2022. 455 [31] Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, 456 Taverner T, Chandan JS, Brown K, Simms-Williams N, Shah AD. Symptoms and risk factors 457 for long COVID in non-hospitalized adults. Nature Medicine. 2022 Jul 25:1-9.